The Effect and Safety of Anti-PD-1 Single/Combination Therapy in Refractory Thymic Carcinoma: A Case-Series Study

Immunotherapy provided with checkpoint inhibitors such as the programmed cell death-1 (PD-1) receptor or its ligand-1 (PD-L1) protein has been shown to be effective for treating several types of cancer, and was recently approved for use in treating malignant melanoma, advanced non-small cell lung ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Wei, Duan, Jian-Chun, Wang, Zhi-Jie, Lin, Lin, Bai, Hua, Wang, Jie, Feng, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7654529/
https://www.ncbi.nlm.nih.gov/pubmed/33192094
http://dx.doi.org/10.2147/CMAR.S274830

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7654529/
https://www.ncbi.nlm.nih.gov/pubmed/33192094
http://dx.doi.org/10.2147/CMAR.S274830

Ejemplares similares